Deerfield Management

Ray Therapeutics is a company focused on developing innovative optogenetic gene therapies aimed at treating patients with blinding diseases. By creating technology that enhances the understanding of rare retinal conditions, the company strives to empower healthcare professionals to effectively diagnose, cure, and manage inherited retinal diseases. Through its commitment to advancing optogenetics, Ray Therapeutics seeks to improve the quality of life for those affected by these debilitating conditions.

Vicinitas Therapeutics is a biotech startup that specializes in developing medicines that impact patient lives. Its vision is to use its proprietary Deubiquitinase Targeting Chimera (DUBTAC) platform to restore the levels of aberrantly degraded proteins that cause disease to confer therapeutic benefit.

InSilico Medicine, Inc. is an artificial intelligence company focused on drug discovery, biomarker development, and aging research. Founded in 2014 and headquartered in Baltimore, Maryland, the company employs advanced AI technologies, including deep learning and generative adversarial networks, to create novel molecular structures for diseases with known and unknown targets. Its comprehensive platform covers all stages of drug development, from discovery to clinical trials. Key initiatives include Pharma.AI, which offers machine learning services to various industries, and Young.AI, which predicts biological age. InSilico Medicine also engages in internal drug discovery programs targeting conditions such as cancer, Parkinson's Disease, and age-related disorders. Additionally, the company has partnered with Life Extension to develop nutraceutical products using its bioinformatics and deep learning techniques. Through its innovative solutions, InSilico Medicine aims to enhance personalized healthcare and mitigate the effects of aging.

Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through innovative testing methods. The company specializes in developing highly sensitive tests to identify and characterize circulating tumor cells (CTCs) from minimally invasive blood samples. Its advanced platform can profile single-cell phenotypes and genotypes, assessing various characteristics such as biomarker expression levels and morphologic traits. Epic Sciences also offers the Oncotype DX AR-V7 Nucleus Detect test for patients with metastatic castration-resistant prostate cancer, along with biopharmaceutical solutions. The company collaborates with biotechnology and pharmaceutical partners, major cancer centers, and research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and provide real-time biopsy material for cancer treatment guidance. Founded in 2008, Epic Sciences is committed to facilitating quick and effective cancer diagnostics.

Acutus Medical, Inc. is an arrhythmia management company that specializes in developing medical technologies for diagnosing and treating complex cardiac arrhythmias. Founded in 2011 and based in Carlsbad, California, the company designs, manufactures, and markets a comprehensive range of tools for catheter-based ablation procedures. Its product offerings include advanced imaging and mapping systems, such as the AcQMap console and workstation, along with diagnostic catheters and therapeutic devices like ablation catheters and robotic navigation systems. Acutus Medical's innovative platform enables electrophysiologists to visualize the heart's activation patterns, facilitating more effective treatment of arrhythmias. The company collaborates with medical scientists and engineers in the U.S. and Europe to enhance its product development and provides solutions to hospitals and electrophysiologists globally.

Operator of a biotechnology company intended for pioneering the development of genetic medicines for treating intractable diseases. The company specializes in developing genetic drugs by simultaneously engineering (Adeno-associated viruses) AAV capsids that bind to the human Transferrin Receptor 1 (TfR1) to enable intravenous delivery of therapeutics that use receptor-mediated transcytosis across the blood brain barrier allowing broad penetration of the central nervous system, and payloads to overcome limitations in cellular access, gene expression, pre-existing immunity and manufacturability, thereby enabling patients to treat debilitating diseases with limited options.

Valneva SE is a specialty vaccine company dedicated to the development and commercialization of vaccines for infectious diseases that lack adequate solutions. The company offers two commercial vaccines for travelers: IXIARO/JESPECT, which protects against Japanese encephalitis, and DUKORAL, aimed at preventing cholera and certain types of diarrhea. Valneva is also advancing several vaccine candidates, including the only developmental vaccine for Lyme disease and a single-shot vaccine for chikungunya. Founded in 1999, Valneva operates in multiple countries, including Austria, Canada, France, Sweden, the United Kingdom, and the United States. The company is involved in a collaboration with Dynavax Technologies Corporation to further vaccine development for COVID-19. Valneva's focus is on addressing urgent public health needs through innovative vaccine solutions.

Based in Seattle, Boston and Tokyo, Aurion Biotech is a clinical-stage biotech company. Our mission is to cure leading forms of blindness and transform the lives of millions of patients, by developing a platform of advanced therapies to treat ocular diseases. Our first candidate is for the treatment of corneal edema, and one of the first clinically validated cell therapies for corneal care. Healthy cells from a donor cornea are cultured in a novel, multi-step, proprietary and patented process. Cells from a single donor can be used to treat more than 100 recipient eyes. In clinical trials in Japan, patients have experienced significant and durable improvements in key measures of corneal health: visual acuity, corneal endothelial cell density and corneal thickness.

Vibliome Therapeutics, Inc. is a biotechnology company based in Bozeman, Montana, that focuses on researching and developing innovative therapeutics. The company is pioneering a non-hormonal birth control pill for men, utilizing the homeodomain-interacting protein kinase 4 (HIPK4) as a key component of its approach. Additionally, Vibliome develops cancer treatments through a specialized library of kinase inhibitors that target specific pathways. With a systematic methodology for creating small molecule kinase inhibitors, Vibliome aims to achieve unique and, in some cases, extraordinary selectivity among the over 500 kinases in the human genome. This versatility in their chemistry platform presents numerous opportunities for advancements in both reproductive health and oncology. Vibliome was incorporated in 2017.

Somatus is a healthcare company that partners with health plans, health systems, and nephrology, and primary care groups. It provides integrated care for patients with or at risk of developing kidney disease. Somatus' is vertically integrated clinical services and technology delay or prevent disease progression, improve quality and care coordination, and increase the use of home dialysis modalities and rates of kidney transplantation. The company is headquartered in McLean, Virginia, and founded by a team of world-class healthcare operators, successful entrepreneurs, and leading clinicians treating kidney disease.

BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, specializing in the development of specific and selective antibody-based therapeutics for cancer treatment. The company utilizes its proprietary platforms, Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!), to create novel monoclonal antibody and cell-based therapeutics. Its lead product candidate, BA3011, is a conditionally active biologic antibody-drug conjugate aimed at treating soft tissue and bone sarcoma, non-small cell lung cancer, and other tumors. BioAtla's pipeline also includes BA3021, targeting non-small cell lung cancer and melanoma, and BA3071, which addresses various cancers such as renal cell carcinoma and bladder cancer. The company's innovative approach enhances drug selectivity for cancer tissues, potentially improving safety and expanding treatment options for previously untreatable cancers. BioAtla holds over 150 issued patents and patent applications, underscoring its commitment to developing safer and more effective cancer therapies.

HilleVax is a clinical-stage biopharmaceutical company established in 2021 and based in Boston, Massachusetts. The company specializes in the development and commercialization of innovative vaccines. Its primary focus is on HIL-214, a vaccine candidate that utilizes virus-like particle (VLP) technology aimed at preventing moderate-to-severe acute gastroenteritis caused by norovirus infection.

ARS Pharmaceuticals, Inc., founded in 2015 and based in San Diego, California, is a biopharmaceutical company specializing in the development of innovative treatments for severe allergic reactions, including anaphylaxis. The company's flagship product, neffy, is a novel intranasal epinephrine spray that utilizes a proprietary absorption technology known as Intravail. This unique formulation allows for effective, injection-like absorption of epinephrine at a low dose, making it a convenient and reliable option for patients at risk of life-threatening allergic reactions to foods, medications, and insect stings. With its focus on enhancing accessibility and ease of use, ARS Pharmaceuticals aims to improve emergency responses for individuals experiencing severe allergic reactions.

PepGen is a clinical-stage biotechnology company based in Oxford, United Kingdom, focused on advancing the delivery of nucleic acid therapeutics, particularly antisense oligonucleotides. Established in 2018, PepGen aims to enhance the clinical efficacy of these therapeutics through its proprietary Enhanced Delivery Oligonucleotide (EDO) platform. This innovative technology employs engineered peptides designed for optimized tissue penetration, cellular uptake, and nuclear delivery, enabling effective transport of oligonucleotides to various target tissues, including smooth, skeletal, and cardiac muscle, as well as the central nervous system. By leveraging its drug delivery capabilities, PepGen seeks to transform the treatment landscape for severe neuromuscular and neurological diseases.

Strata Oncology is a precision oncology company focused on enhancing cancer care through increased access to clinical trials and expediting drug approval processes. Based in Ann Arbor, Michigan, Strata develops a comprehensive oncology platform that facilitates routine genomic testing and the efficient use of molecular data. Its offerings include The Strata Trial, a genomic testing protocol aimed at implementing enterprise-wide precision oncology; StrataNGS, a targeted assay for sequencing DNA and RNA from biopsy samples; and StrataPOINT, which integrates electronic medical record data with molecular profiling to ensure eligible patients are tested and considered for precision trials. Additionally, the company manages Strata Partnered Trials, a collection of pharmaceutical-sponsored protocols linked to specific biomarkers, and operates The Strata Lab, a cancer sequencing facility. Through its collaborative network of cancer centers, Strata is dedicated to advancing precision medicine for patients with cancer, ultimately providing actionable insights for healthcare providers.

Frontier Medicines Corporation is a pre-clinical stage biopharmaceutical company based in South San Francisco, California, founded in 2018. The company specializes in discovering and developing medicines that target cancer-causing proteins through its innovative chemoproteomics platform. This platform utilizes advanced computational techniques and machine learning to identify new binding pockets on proteins, thereby facilitating the discovery and development of small-molecule drugs. By enhancing the drug development process, Frontier Medicines aims to deliver breakthrough therapies that can significantly change the treatment landscape for debilitating diseases.

Talkspace Network LLC is a behavioral healthcare company based in New York that provides accessible mental health therapy through a technology platform. Founded in 2012, it offers services such as unlimited messaging therapy, teen therapy, couple therapy, and therapy tailored for businesses. Users can communicate with licensed therapists via text, audio, and video messaging, allowing for a confidential and convenient alternative to traditional face-to-face therapy. This format is particularly beneficial for individuals who may struggle to open up in person or find conventional therapy sessions prohibitively expensive. Talkspace's platform is designed to address a variety of mental health conditions, and it serves a diverse clientele, including health plans, enterprises, and individual subscribers. The company primarily generates revenue from contracts with payors and direct-to-enterprise clients, with a significant focus on the U.S. market.

Synthekine Inc. is a biotechnology company focused on the development of engineered cytokine therapies and immunotherapies aimed at treating cancer and autoimmune disorders. Founded in 2018 and based in Menlo Park, California, Synthekine utilizes innovative platform technologies, including engineered partial agonists and orthogonal cell therapies, to create differentiated therapeutics. Its product pipeline features STK-009, an orthogonal ligand, and SYNCAR-001, a CAR-T therapy modified with orthogonal receptors. Additionally, the company is advancing STK-012, a partial agonist of IL-2, alongside Synthekines, which are designed to enhance signaling activities by combining cytokine receptors without relying on wild-type cytokines. Synthekine's approach is informed by immunological insights to ensure that its treatments are both safe and effective, with promising preclinical results indicating potential for improved efficacy and tolerability.

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.

ADC Therapeutics is a clinical-stage oncology drug discovery and development company focused on advancing highly potent and targeted antibody drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. Our ADCs are developed using the latest-generation pyrrolobenzodiazepine (PBD) dimer technology providing a superior therapeutic index compared to first- generation PBD ADCs in preclinical studies. PBD dimers are very potent toxins that actively kill cancer cells and have a differentiated mechanism of action than warheads commonly used in other ADCs.

Adaptive Phage Therapeutics, Inc. specializes in developing therapeutic solutions to combat the increasing threat of multi-drug resistant (MDR) bacteria. Founded in 2016 and based in Gaithersburg, Maryland, the company utilizes a unique resource known as PhageBank, which is an extensive and dynamic collection of bacteriophages—viruses that specifically target and attack harmful bacteria. Through a rapid system that matches these phages to individual patient bacterial infections, Adaptive Phage Therapeutics aims to enhance treatment options for patients suffering from MDR infections. Their innovative approach enables medical researchers to create tailored therapies that effectively detect and eliminate resistant bacterial strains.

Nuvalent is a biotechnology company that develops targeted therapies for clinically proven kinase targets in cancer. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. It is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs. It was founded in 2017 and is based in Cambridge, Massachusetts.

Jaguar Gene Therapy is a clinical-stage biotechnology company focused on advancing gene therapy solutions for patients with severe genetic diseases. The company aims to address significant unmet medical needs by developing therapies that target nonworking or absent genes, introducing healthy copies of these genes to restore their function. By accelerating the process of bringing innovative gene therapies from research to clinical application, Jaguar Gene Therapy seeks to improve patient outcomes and enhance the overall standard of care for those affected by genetic disorders.

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.

Xeris Biopharma is a specialty pharmaceutical company focused on developing and commercializing ready-to-use injectable and infusible drug formulations. Utilizing its proprietary XeriSol and XeriJect technology platforms, the company delivers highly concentrated, liquid-stable formulations of peptides, small molecules, and proteins through various delivery methods, including syringes and auto-injectors. Xeris Biopharma's lead product is Gvoke, a ready-to-use glucagon for treating severe hypoglycemia, while its other products include Keveyis, the first FDA-approved treatment for primary periodic paralysis, and Recorlev, approved for endogenous hypercortisolemia in Cushing's Syndrome. The company is also advancing several product candidates in clinical trials, targeting conditions in endocrinology, neurology, and gastroenterology. Founded in 2005 and headquartered in Chicago, Illinois, Xeris Biopharma aims to improve patient care by providing easier-to-use therapies that enhance treatment outcomes.

Jaguar Gene Therapy is a clinical-stage biotechnology company focused on advancing gene therapy solutions for patients with severe genetic diseases. The company aims to address significant unmet medical needs by developing therapies that target nonworking or absent genes, introducing healthy copies of these genes to restore their function. By accelerating the process of bringing innovative gene therapies from research to clinical application, Jaguar Gene Therapy seeks to improve patient outcomes and enhance the overall standard of care for those affected by genetic disorders.

Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States.

Spectrawave, Inc. is a medical device company based in Waltham, Massachusetts, founded in 2017. The company specializes in developing and manufacturing optical diagnostic and therapeutic devices aimed at enhancing the diagnosis and treatment of cardiovascular diseases. One of its key innovations is a spectroscopy catheter that integrates advanced imaging technologies to improve outcomes for patients with coronary artery disease (CAD). This cutting-edge imaging system provides interventional cardiologists with crucial optical and computational insights, enabling them to identify patients and plaque formations that may pose risks for future coronary complications. Through its focus on photonics, Spectrawave aims to optimize stent interventions and improve overall patient care in the field of cardiovascular medicine.

Nuvalent is a biotechnology company that develops targeted therapies for clinically proven kinase targets in cancer. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. It is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs. It was founded in 2017 and is based in Cambridge, Massachusetts.

Werewolf Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cancer immunotherapies. Founded in 2017, the company is advancing a pipeline of therapeutic candidates designed to stimulate the immune system specifically within the tumor microenvironment. Utilizing its proprietary PREDATOR platform, Werewolf Therapeutics engineers conditionally activated molecules known as INDUKINE, which remain inactive in peripheral tissues but activate selectively in the presence of tumors. This targeted approach aims to enhance both adaptive and innate immune responses, addressing limitations associated with traditional proinflammatory therapies. Through its research and development efforts, Werewolf Therapeutics is committed to transforming cancer treatment.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral, small-molecule drugs for the treatment of cancer and liver diseases, particularly non-alcoholic steatohepatitis (NASH). Founded in 2017 and headquartered in Foster City, California, with additional offices in Shanghai, the company leverages its expertise in disease biology and medicinal chemistry to advance a pipeline of innovative therapeutic candidates. Key products include TERN-101, a non-bile acid farnesoid X receptor agonist, and TERN-201, an inhibitor of semicarbazide-sensitive amine oxidase. Terns Pharmaceuticals aims to address significant unmet medical needs both in China and globally through its efficient drug discovery model and extensive clinical development capabilities.

FogPharma is a healthcare company founded in 2015 and headquartered in Gloucester, Massachusetts. The firm is dedicated to the pharmaceutical sector, with a primary focus on developing innovative treatments for cancer. It operates with the support of a diverse group of private and institutional investors, fostering collaboration among its founders, employees, and advisors. FogPharma aims to create a new class of medicines designed to extend and enhance the lives of cancer patients. The company's commitment to its mission drives its efforts to pioneer effective solutions in cancer treatment.

Neomorph, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing protein degradation solutions, specifically through the use of molecular glue degraders. This innovative approach repurposes the cellular machinery to eliminate proteins associated with various diseases, particularly targeting those considered "undruggable." Neomorph's mission is to address critical challenges in human health by discovering and creating new medicines aimed at these difficult targets, thereby advancing its projects through clinical development.

Cystetic Medicines develops a treatment that potentially could help people with cystic fibrosis (CF), regardless of genetic mutation.

Octave Bioscience is an early-stage molecular diagnostics company based in Menlo Park, California, that specializes in neurodegenerative diseases, particularly multiple sclerosis. Co-founded in 2013 by Melinda Thomas and William Hagstrom, the company has developed a clinical platform that generates, analyzes, and integrates data to transform the care of neurodegenerative conditions. This platform adopts a multi-dimensional approach aimed at reducing overall healthcare costs through the optimization of medication use and healthcare services. Additionally, Octave's technology supports the pharmaceutical industry by enhancing the drug discovery process, clinical trials, and post-marketing activities through real-world evidence.

Bridge Medicines LLC offers drug discovery services. It focuses on developing technologies in academic institutions from human proof-of-concept to clinical development. The company develops inhibitors of ENL-YEATS for the treatment of acute leukemias, such as acute myelogenous leukemia and a series of orally active small molecule inhibitors of activated factor XII for the treatment of hereditary angioedema and other inflammatory disorders. Bridge Medicines LLC was founded in 2016 and is based in New York, New York.

Springtide Child Development, Inc. provides child development services. It offers personalized and holistic treatment plans. The company provides Applied behavior analysis therapy for autism, speech therapy, occupational therapy, physical therapy, language acquisition, social skills, school readiness, and functional living skill development services. Springtide Child Development, Inc. was incorporated in 2018 and is based in Trumbull, Connecticut.

InCarda Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops transformative therapies for cardiovascular diseases that enable patients to use in the first moments of acute cardiovascular symptoms. The company develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. InCarda Therapeutics, Inc. was formerly known as Pleiades Cardio-Therapeutics, Inc. and changed its name to InCarda Therapeutics, Inc. in May 2011. The company was founded in 2009 and is based in Newark, California.

Curation Health, LLC offers a clinical decision support platform designed to facilitate the transition from fee-for-service to value-based care. Founded in 2018 and based in Annapolis, Maryland, the company provides a point-of-care solution that integrates with electronic health records to deliver actionable risk adjustment insights. This platform captures accurate clinical data before and after patient visits, ensuring comprehensive provider documentation. Curation Health's services enhance performance for various healthcare programs, including Medicare Advantage, MSSP, Medicaid risk programs, and quality initiatives based on standard measures. By leveraging clinical and quality rules, the platform aims to improve documentation processes and the overall value of patient care.

Olema Oncology is a clinical-stage biopharmaceutical company dedicated to developing targeted therapies for women's cancers, particularly estrogen receptor (ER)-positive breast cancer. The company's lead candidate, OP-1250, is an ER antagonist and selective ER degrader currently undergoing Phase 1/2 clinical trials for the treatment of metastatic or locally advanced, ER-positive, and human epidermal growth factor receptor 2-negative breast cancer. Olema's research focuses on utilizing its expertise in endocrine-driven cancers and the molecular mechanisms of the ER to create more effective treatments that aim to improve patient outcomes. In addition to OP-1250, Olema is advancing another drug candidate, OP-3136, further enriching its pipeline. Established in 2006 and headquartered in San Francisco, California, Olema is committed to transforming the standard of care for women facing these challenging diagnoses.

Reprieve Cardiovascular, Inc., a medical device company, develops and manufactures a medical fluid management device for congestive heart failure. It offers Reprieve technology, a fluid management therapy solution providing clinicians with the ability to precisely control a patient’s fluid volume for acute decompensated heart failure (ADHF) patients. The company was founded in 2018 and is based in Milford, Massachusetts. Reprieve Cardiovascular, Inc. operates as a subsidiary of CardioRenal Systems, Inc.

Annexon Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for autoimmune and neurodegenerative diseases that are influenced by the classical complement pathway. The company’s research revolves around C1q, a key molecule that, when aberrantly activated, contributes to various disease processes. Its lead product candidates include ANX005, a monoclonal antibody designed for intravenous administration, which has completed Phase 1b trials for treating Guillain-Barré syndrome, and ANX007, formulated for intravitreal use, which has also completed Phase 1b trials aimed at glaucoma treatment. Additionally, Annexon is advancing preclinical candidates targeting conditions such as warm autoimmune hemolytic anemia, Huntington's disease, amyotrophic lateral sclerosis, and geographic atrophy. Founded in 2011 and headquartered in South San Francisco, California, the company employs a biomarker-driven strategy to ensure effective engagement of its therapies in the intended patient populations.

Somatus is a healthcare company that partners with health plans, health systems, and nephrology, and primary care groups. It provides integrated care for patients with or at risk of developing kidney disease. Somatus' is vertically integrated clinical services and technology delay or prevent disease progression, improve quality and care coordination, and increase the use of home dialysis modalities and rates of kidney transplantation. The company is headquartered in McLean, Virginia, and founded by a team of world-class healthcare operators, successful entrepreneurs, and leading clinicians treating kidney disease.

Meditrina, Inc., founded in 2016 and based in San Jose, California, specializes in developing innovative medical devices for tissue removal solutions related to intrauterine pathology. The company provides the Aveta system, designed for healthcare professionals to facilitate hysteroscopic diagnostic and therapeutic procedures, including the removal of polyps and fibroids. In addition to its tissue removal products, Meditrina is also focused on creating fully disposable endoscopes and a comprehensive visualization system intended for use in both office and clinical settings, catering to various medical procedures.

ARTMS Products Inc. is a Vancouver-based company that specializes in manufacturing diagnostic imaging systems for the production and separation of medical isotopes. Founded in 2013, the company has developed the QUANTM Irradiation System, which facilitates decentralized and local production of critical isotopes such as gallium-68, zirconium-89, technetium-99m, and copper-64. ARTMS's primary offering, QUANTM99, is a system that combines hardware and consumables for the effective production of technetium-99m using medical cyclotrons. This innovative approach aims to enhance the accessibility and cost-effectiveness of medical isotopes, improving diagnostic imaging services.

ADC Therapeutics is a clinical-stage oncology drug discovery and development company focused on advancing highly potent and targeted antibody drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. Our ADCs are developed using the latest-generation pyrrolobenzodiazepine (PBD) dimer technology providing a superior therapeutic index compared to first- generation PBD ADCs in preclinical studies. PBD dimers are very potent toxins that actively kill cancer cells and have a differentiated mechanism of action than warheads commonly used in other ADCs.

Intersect ENT is a medical device company focused on developing innovative therapies for patients with ear, nose, and throat conditions in the United States. The company specializes in drug delivery products, including the PROPEL and PROPEL mini drug-releasing implants, designed for individuals undergoing sinus surgery to address chronic sinusitis. Additionally, it offers PROPEL Contour, a steroid-releasing implant aimed at treating frontal and maxillary sinus ostia. Intersect ENT also provides SINUVA, a steroid-releasing implant intended for use in the physician's office for patients with refractory disease. Founded in 2003 and headquartered in Menlo Park, California, the company was previously known as Sinexus before rebranding in 2009.

Farapulse, Inc. develops and commercializes catheter-based tools specifically designed for the treatment of atrial fibrillation. Founded in 2012 and based in Menlo Park, California, the company offers an innovative product known as FARAWAVE, which utilizes advanced tissue-selective pulsed field ablation (PFA) therapy. This therapy is available on both catheter and surgical platforms for endocardial and epicardial applications. Farapulse's product range includes various catheter types, such as over-the-wire, deflectable, linear, and circumferential lesion catheters, which enable doctors to isolate pulmonary veins safely and effectively. The company's mission is to enhance the safety, speed, accessibility, and affordability of atrial fibrillation ablation for patients worldwide.

Generation Bio is a genetic medicines company based in Cambridge, Massachusetts, that specializes in developing gene therapies aimed at treating both rare and prevalent diseases. Established in 2016, the company focuses on conditions affecting the liver, retina, skeletal muscle, central nervous system, and oncology. Generation Bio employs an innovative non-viral platform that includes a proprietary high-capacity DNA construct known as closed-ended DNA (ceDNA), a cell-targeted lipid nanoparticle delivery system (ctLNP), and a scalable, capsid-free manufacturing process. This approach allows for the targeted delivery of genetic materials, including large and multiple genes across various tissues, and enables redosable treatments tailored to individual patient needs. By enhancing access to therapies for rare diseases and addressing more common conditions, Generation Bio aims to provide durable and sustainable treatment options for patients throughout their lives.

Neomorph, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing protein degradation solutions, specifically through the use of molecular glue degraders. This innovative approach repurposes the cellular machinery to eliminate proteins associated with various diseases, particularly targeting those considered "undruggable." Neomorph's mission is to address critical challenges in human health by discovering and creating new medicines aimed at these difficult targets, thereby advancing its projects through clinical development.

Four Points Innovation supports Duke R&D projects throughout preclinical stages of drug discovery and development. Beginning approximately in March 2020, Duke researchers can submit proposals on projects for consideration by a Four Points Innovation committee comprised of scientific leadership representing Duke and Deerfield.

Black Diamond Therapeutics is a precision oncology medicine company focused on discovering and developing small molecule, tumor-agnostic therapies. The company's lead product candidate, BDTX-189, is designed to inhibit specific mutations in ErbB kinases, including the epidermal growth factor receptor. Additionally, Black Diamond is advancing a pipeline of allosteric-EGFR mutation inhibitors and other early-stage programs targeting allosteric mutations in kinases associated with cancer and rare genetic diseases. The company employs a technology platform known as Mutation-Allostery-Pharmacology, which aims to address undrugged mutations in patients with genetically defined cancers. Founded in 2014 and based in Cambridge, Massachusetts, Black Diamond Therapeutics was previously known as ASET Therapeutics until its rebranding in 2018.

Civetta Therapeutics, LLC is a biotechnology company based in Cambridge, Massachusetts, focused on developing small molecule therapeutics that target beta-propeller proteins for the treatment of cancers and other diseases. Founded in 2018, Civetta leverages its expertise in biochemistry, biology, and medicinal chemistry to create innovative therapies aimed at modulating the diverse functional roles of propeller proteins, which are critical in various disease pathways, including cancer and neurodegeneration. The company aims to build a robust portfolio of therapeutics that provide both immediate treatment options and long-term value in the biopharmaceutical landscape. Through its targeted approach, Civetta seeks to enhance the availability of effective treatment options for healthcare providers and patients facing serious health challenges.

Edgewise Therapeutics is a clinical-stage biopharmaceutical company based in Boulder, Colorado, specializing in the development of small molecule therapies for severe musculoskeletal diseases. Founded in 2017, the company leverages its expertise in skeletal muscle physiology to create innovative treatments for genetically defined muscle disorders, including Duchenne, Becker, and limb girdle muscular dystrophies. Edgewise Therapeutics employs a precision medicine platform to identify and target key muscle proteins and modulators, aiming to address the underlying causes of these conditions. Additionally, the company has established a state-of-the-art research facility to enhance its capabilities in understanding muscle adaptation and injury related to disease.

Nkarta Therapeutics is a biopharmaceutical company focused on developing engineered natural killer (NK) cell therapies for cancer treatment. Founded in 2015 and headquartered in South San Francisco, California, Nkarta aims to enhance the efficacy and tolerability of cell therapies, addressing both hematologic and solid tumor malignancies. The company's approach utilizes chimeric antigen receptors on NK cells, enabling them to recognize and attack tumor cells more effectively. Nkarta's lead product candidates include NKX101, designed to harness innate NK cell biology for cancer detection and destruction, and NKX019, targeting the CD19 antigen to treat various B cell malignancies. By leveraging its NK expansion platform and proprietary cell engineering technologies, Nkarta seeks to provide a more potent and accessible treatment option, capitalizing on the natural ability of NK cells to identify and eliminate abnormal cells while minimizing side effects typically associated with other therapies.

Frequency Therapeutics is a clinical-stage biotechnology company based in Woburn, Massachusetts, dedicated to leveraging the body's natural biology to repair or reverse damage from various degenerative diseases. The company employs a unique Progenitor Cell Activation approach, utilizing combinations of small molecules to stimulate progenitor cells to regenerate functional tissue. Its lead product candidate, FX-322, is currently undergoing phase 2a clinical trials aimed at addressing the underlying causes of sensorineural hearing loss. In addition to hearing loss, Frequency Therapeutics is developing therapies for a variety of degenerative conditions, including multiple sclerosis and ailments affecting muscle, skin, gastrointestinal tract, and bone health. The company has also established a collaboration agreement with Astellas Pharma for the development and commercialization of FX-322. Founded in 2014, Frequency Therapeutics is focused on disease modification through innovative therapeutic strategies.

Developer of a healthcare device designed to reduce sympathetic nerve activity and address the root cause of heart failure. The company's device allows clinicians to ablate the right greater splanchnic nerve using a small catheter inserted through the groin and helps to normalize sympathetic nervous activity, to shift blood volume from the heart back to the splanchnic bed, reducing pressures in the heart, enabling clinicians to begin treatment quickly, resulting in a higher likelihood of successful treatment.

Frontier Medicines Corporation is a pre-clinical stage biopharmaceutical company based in South San Francisco, California, founded in 2018. The company specializes in discovering and developing medicines that target cancer-causing proteins through its innovative chemoproteomics platform. This platform utilizes advanced computational techniques and machine learning to identify new binding pockets on proteins, thereby facilitating the discovery and development of small-molecule drugs. By enhancing the drug development process, Frontier Medicines aims to deliver breakthrough therapies that can significantly change the treatment landscape for debilitating diseases.

Aerie Pharmaceuticals is an ophthalmic pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for various eye diseases, including glaucoma, dry eye, and retinal conditions. The company's key products include Rhopressa, a once-daily eye drop that lowers elevated intraocular pressure in glaucoma patients, and Rocklatan, a fixed-dose combination of Rhopressa and latanoprost for treating open-angle glaucoma and ocular hypertension. Additionally, Aerie is advancing its clinical-stage product AVX-012 for dry eye and developing sustained-release implants AR-1105 and AR-13503 for retinal diseases. Established in 2005, Aerie is headquartered in Durham, North Carolina, with research facilities in Research Triangle Park. The company has also formed a collaborative research and development agreement with DSM.

TriNetX, Inc. is a global health research network that facilitates collaboration among healthcare organizations, biopharmaceutical companies, and contract research organizations. The company provides a platform that enables researchers to analyze patient populations and derive real-world evidence, thereby enhancing trial design and improving site selection. Key offerings include TriNetX Live, a cloud-based solution for real-time analytics; TriNetX Research, which delivers longitudinal clinical data; and TriNetX Download, a platform for accessing real-world clinical data. Additionally, TriNetX features Attract Trials for data alignment in collaboration, Natural Language Processing for extracting clinical insights from physician documentation, and specialized tools for oncology research. Established in 2013 and headquartered in Cambridge, Massachusetts, TriNetX also has offices in Sydney, London, and Sao Paulo, and maintains compliance with HIPAA and GDPR regulations.

Black Diamond Therapeutics is a precision oncology medicine company focused on discovering and developing small molecule, tumor-agnostic therapies. The company's lead product candidate, BDTX-189, is designed to inhibit specific mutations in ErbB kinases, including the epidermal growth factor receptor. Additionally, Black Diamond is advancing a pipeline of allosteric-EGFR mutation inhibitors and other early-stage programs targeting allosteric mutations in kinases associated with cancer and rare genetic diseases. The company employs a technology platform known as Mutation-Allostery-Pharmacology, which aims to address undrugged mutations in patients with genetically defined cancers. Founded in 2014 and based in Cambridge, Massachusetts, Black Diamond Therapeutics was previously known as ASET Therapeutics until its rebranding in 2018.

Stelexis Therapeutics, LLC is focused on researching and developing therapies aimed at pre-cancerous stem cells. Established in 2017 and headquartered in New York, the company utilizes its proprietary drug discovery platform to identify stem and progenitor cells that contribute to the formation of primary and recurrent tumors. Stelexis aims to create cancer drugs that specifically target pre-cancerous events associated with both hematopoietic malignancies, such as acute myeloid leukemia, and solid tumors. By concentrating on the earliest definable pre-cancerous stem cells, the company seeks to enable healthcare providers to intervene early and prevent the progression of cancer.

Schrödinger is a healthcare software company that specializes in computational drug design, serving the biopharmaceutical and biotechnology sectors. Founded in 1990, the company operates through two main segments: Software and Drug Discovery. Its software solutions facilitate drug discovery processes for pharmaceutical and industrial clients, as well as academic and governmental research institutions. In addition to software sales, Schrödinger engages in drug discovery through its own preclinical and clinical programs, often collaborating with other organizations. The company is committed to advancing its computational platform by investing in scientific research and talent, and it has established partnerships and collaborations across more than 70 countries. With a workforce of over 400 employees, Schrödinger continues to influence the life sciences and materials science industries through innovative approaches to drug discovery.

InCarda Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops transformative therapies for cardiovascular diseases that enable patients to use in the first moments of acute cardiovascular symptoms. The company develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. InCarda Therapeutics, Inc. was formerly known as Pleiades Cardio-Therapeutics, Inc. and changed its name to InCarda Therapeutics, Inc. in May 2011. The company was founded in 2009 and is based in Newark, California.

SHINE Medical Technologies, LLC is a manufacturer and supplier of medical tracers and cancer treatment elements, specializing in isotopes used for diagnostic and therapeutic purposes. The company produces molybdenum-99, which is essential for imaging and diagnosing conditions such as cancer and heart disease. Additionally, SHINE offers Iodine-131 for the treatment of thyroid cancer and related conditions, as well as Iodine-125, which is utilized in brachytherapy for various cancers. The company also provides Xenon-133, an inhalable gas that assists in evaluating lung function and blood flow in the brain. Founded in 2010 and headquartered in Janesville, Wisconsin, SHINE serves both domestic and international markets with its innovative medical solutions.

Tris Pharma, Inc. is a specialty pharmaceutical company based in Monmouth Junction, New Jersey, that focuses on the research, development, manufacturing, and marketing of over-the-counter, prescription branded, and specialty generic products in the United States. The company specializes in extended release formulations tailored for children, seniors, and adults who have difficulty swallowing pills. Tris Pharma has developed several proprietary technologies, including OralXR+, which delivers medication over time using small particles, and Nobuse, an abuse-resistant technology. The product portfolio includes immediate and extended release formulations, lipophilic drugs, and Tuzistra XR, an extended-release oral suspension for cough relief. The company offers a diverse range of dosage forms, including suspensions, chewable tablets, and film strips, and has a pipeline of products targeting cough and cold, pain management, and neurological disorders. Established in 2000, Tris Pharma holds over 30 U.S. patents and has successfully commercialized numerous products in the market through both internal resources and licensing agreements.

Trinity Biotech is engaged in the development, manufacturing, and marketing of medical diagnostic products for clinical laboratories and point-of-care settings. The company offers a wide range of diagnostic tests and instrumentation that detect infectious diseases, sexually transmitted infections, autoimmune disorders, and conditions related to diabetes and liver health. With a portfolio of over 400 products, it employs various diagnostic formats, including immunofluorescence assays and enzyme-linked immunosorbent assays. Additionally, Trinity Biotech supplies raw materials to the life sciences and research sectors. Its products are marketed under several brand names, including Recombigen and Unigold, and are sold through a direct sales force and a network of independent distributors. The company serves a diverse clientele, including public health facilities, hospitals, and clinical laboratories. Founded in 1992 and headquartered in Bray, Ireland, Trinity Biotech has established a strong presence in the diagnostic market across regions including the Americas, Europe, Africa, and Asia.

Pinnacle Hill is a collaboration between the University of North Carolina at Chapel Hill and Deerfield Management, focused on discovering new medicines to address significant unmet medical needs. The company develops therapeutic medical drugs targeting diseases such as multiple myeloma and Angelman syndrome. Its innovative approach aims to replace or reactivate the faulty UBE3A gene in affected nerve cells, providing healthcare professionals with new treatment options for patients facing life-threatening conditions. Deerfield Management contributes up to $65 million in targeted funding and offers drug development expertise to enhance the promising therapeutic research at UNC-Chapel Hill.

ARS Pharmaceuticals, Inc., founded in 2015 and based in San Diego, California, is a biopharmaceutical company specializing in the development of innovative treatments for severe allergic reactions, including anaphylaxis. The company's flagship product, neffy, is a novel intranasal epinephrine spray that utilizes a proprietary absorption technology known as Intravail. This unique formulation allows for effective, injection-like absorption of epinephrine at a low dose, making it a convenient and reliable option for patients at risk of life-threatening allergic reactions to foods, medications, and insect stings. With its focus on enhancing accessibility and ease of use, ARS Pharmaceuticals aims to improve emergency responses for individuals experiencing severe allergic reactions.

Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through innovative testing methods. The company specializes in developing highly sensitive tests to identify and characterize circulating tumor cells (CTCs) from minimally invasive blood samples. Its advanced platform can profile single-cell phenotypes and genotypes, assessing various characteristics such as biomarker expression levels and morphologic traits. Epic Sciences also offers the Oncotype DX AR-V7 Nucleus Detect test for patients with metastatic castration-resistant prostate cancer, along with biopharmaceutical solutions. The company collaborates with biotechnology and pharmaceutical partners, major cancer centers, and research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and provide real-time biopsy material for cancer treatment guidance. Founded in 2008, Epic Sciences is committed to facilitating quick and effective cancer diagnostics.

Allogene Therapeutics is a clinical-stage biotechnology company focused on immuno-oncology, particularly the development of genetically engineered allogeneic T cell therapies for cancer treatment. The company is advancing a pipeline of allogeneic T cell product candidates that leverage validated gene editing and proprietary cell manufacturing technologies. Key offerings include UCART19, which targets relapsed or refractory acute lymphoblastic leukemia, alongside several preclinical allogeneic CAR T therapies aimed at various malignancies and autoimmune diseases. By using T cells derived from healthy donors, Allogene Therapeutics aims to provide off-the-shelf treatment options that enhance patient eligibility and scalability. The company seeks to redefine CAR T therapy through its innovative approaches, addressing conditions like lymphoma, leukemia, and solid tumors.

Poseidon Innovation specializes in the development of advanced therapeutics aimed at curing diseases, particularly for patients in risky early-stage conditions. Operating primarily in New York, the company focuses on streamlining the drug development cycle, allowing for quicker access to treatments. By addressing the complexities and uncertainties associated with early-stage therapeutic processes, Poseidon Innovation seeks to enhance the efficiency of bringing new medical solutions to patients in need.

Appello Pharmaceuticals, Inc. is a preclinical-stage company based in Nashville, Tennessee, specializing in the development of innovative positive allosteric modulators of mGlu4. These compounds are being investigated for their potential in treating Parkinson’s disease. The company aims to advance its research to provide new therapeutic options for this neurological disorder.

Ablexis, LLC, a biotechnology company, provides a platform for human antibody drug discovery and development. The company offers AlivaMab Mouse, a transgenic mouse platform for the discovery and development of therapeutic antibodies to treat human diseases. It commercializes its platform through creative partnering strategies to biotechnology and pharmaceutical companies. The company was founded in 2009 and is based in San Francisco, California.

Cureatr Inc. offers a mobile care coordination solution aimed at improving medication management for healthcare providers. By integrating HIPAA-secure text messaging with workflow navigation tools, Cureatr facilitates efficient communication among medical teams. The platform is accessible on Web, Android, and iPhone devices, ensuring real-time, universal access to accurate medication data for over 265 million patients. The company addresses the significant challenges of suboptimal medication management in the United States, which leads to substantial healthcare costs and mortality. With a focus on high-quality interventions provided by board-certified telepharmacists, Cureatr aims to enhance patient safety and reduce hospitalizations. Established in 2011, the company is headquartered in New York, New York.

Sollis Therapeutics, Inc. is a clinical-stage pharmaceutical company based in Columbus, Ohio, focused on developing non-steroid, non-opioid analgesics and anti-inflammatory medications. Its primary product, Radicular Pain RelIEf Via Epidural injection of Clonidine Micropellets (RePRIEVE-CM), is designed for targeted local delivery to address lumbosacral radiculopathy, sciatica, and other neuropathic pain syndromes. Founded in 2017, Sollis Therapeutics aims to provide effective pain management solutions while avoiding the complications associated with traditional opioid treatments. Through its innovative approach, the company seeks to improve therapeutic options for healthcare providers managing pain conditions that affect a significant number of individuals.

Arvinas is a pharmaceutical company that focuses on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Its proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body. The company was founded in 2013 and is headquartered in Connecticut, United States.

Operator of a novel therapeutics company intended to accelerate early-stage therapeutics based on novel biology. The company focuses on identifying and establishing development plans for the advancement of novel drugs to market, enabling scientists to execute novel and potentially transformative research projects.

Dracen Pharmaceuticals, Inc. is a biotechnology company based in Baltimore, Maryland, founded in 2016. The company specializes in the discovery and development of anticancer therapies, focusing on novel glutamine antagonists. These innovative therapies aim to directly reduce tumor size and improve the tumor microenvironment, thereby enhancing the effectiveness of immuno-oncology treatments. Dracen's approach seeks to increase the number of patients who respond to cancer therapies and extend survival rates, particularly in cases where traditional immuno-oncology methods have been less effective. Through its commitment to advancing cancer treatment, Dracen Pharmaceuticals is dedicated to improving outcomes for cancer patients.

Generation Bio is a genetic medicines company based in Cambridge, Massachusetts, that specializes in developing gene therapies aimed at treating both rare and prevalent diseases. Established in 2016, the company focuses on conditions affecting the liver, retina, skeletal muscle, central nervous system, and oncology. Generation Bio employs an innovative non-viral platform that includes a proprietary high-capacity DNA construct known as closed-ended DNA (ceDNA), a cell-targeted lipid nanoparticle delivery system (ctLNP), and a scalable, capsid-free manufacturing process. This approach allows for the targeted delivery of genetic materials, including large and multiple genes across various tissues, and enables redosable treatments tailored to individual patient needs. By enhancing access to therapies for rare diseases and addressing more common conditions, Generation Bio aims to provide durable and sustainable treatment options for patients throughout their lives.

ReMed is a brain injury rehabilitation company.

Kiniksa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with a significant unmet medical need. It has a pipeline of product candidates across various stages of development, currently focused on autoinflammatory and autoimmune conditions. It has three clinical-stage product candidates, one of which is anticipated to commence a Phase 3 clinical trial in 2018. They follow a disciplined and methodical approach to selectively identify and acquire product candidates with strong biologic rationales or validated mechanisms of action. The company's portfolio of product candidates offers multiple development opportunities. By modulating different parts of the innate and adaptive immune system, these product candidates together have the potential to provide a variety of mechanisms to address multiple devastating diseases.

Quartet Health, Inc. is a healthcare technology company that operates a cloud-based platform designed to enhance communication and collaboration between medical and behavioral health providers. Founded in 2014 and based in New York, the company partners with health plans and health systems to deliver actionable insights and reports on behavioral health conditions, ultimately aiming to improve patient outcomes. Quartet's platform facilitates access to suitable mental health care tailored to individual preferences and clinical needs, ensuring that care is compatible with patients' insurance plans. By connecting physicians, mental health providers, and insurance companies, Quartet seeks to improve the overall health of patients while also reducing healthcare costs.

Fractyl Health Inc. is a medical device company specializing in innovative therapies for metabolic diseases, particularly type 2 diabetes and obesity. The company's flagship product, Revita DMR, is a minimally invasive procedure that utilizes hydrothermal ablation to rejuvenate the lining of the duodenum, effectively addressing the underlying causes of these conditions. By focusing on transforming the treatment of metabolic diseases from merely managing symptoms to providing durable, disease-modifying solutions, Fractyl Health aims to significantly improve patient health outcomes. Founded in 2010 and based in Lexington, Massachusetts, the company is committed to developing curative therapies that lessen the burden on patients, healthcare providers, and payers.

Melinta Therapeutics, Inc. is a commercial-stage pharmaceutical company specializing in the discovery, development, and commercialization of anti-infective therapies targeting bacterial infections. The company offers several products, including Baxdela, Vabomere, Orbactiv, and Minocin, which address various acute bacterial skin infections and gram-negative infections. Recognizing the urgent need for new antibiotics to combat drug-resistant infections, Melinta is advancing delafloxacin, currently in Phase 3 development for treating acute bacterial skin and skin structure infections. The company also focuses on developing innovative antibiotics aimed at overcoming resistant pathogens associated with serious hospital infections. Established in 2000, Melinta Therapeutics is headquartered in Morristown, New Jersey, and operates with support from strategic partners in the healthcare sector.

Homology Medicines, Inc. is a genetic medicines company based in Bedford, Massachusetts, focused on improving the lives of patients with rare genetic diseases. The company employs a proprietary platform that utilizes human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to deliver genetic therapies in vivo, either through gene therapy or nuclease-free gene editing. This innovative approach allows for targeted treatment of various disease-relevant tissues, including the liver and central nervous system, through a single injection. Homology's lead product candidate, HMI-102, is currently in a Phase 1/2 clinical trial for treating phenylketonuria (PKU) in adults, while HMI-103 targets pediatric PKU patients, and HMI-202 is being developed for metachromatic leukodystrophy. Founded in 2015, Homology Medicines aims to address significant unmet medical needs by targeting the underlying causes of genetic disorders.

Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases. The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics. Proteon Therapeutics’ first drug candidate (PRT-201) is in development for the improvement of blood flow following vascular surgery procedures. The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD).

Aziyo is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. From our proprietary tissue processing platforms, we have developed a portfolio of advanced regenerative medical products that are designed to be very similar to natural biological material.

Xeris Biopharma is a specialty pharmaceutical company focused on developing and commercializing ready-to-use injectable and infusible drug formulations. Utilizing its proprietary XeriSol and XeriJect technology platforms, the company delivers highly concentrated, liquid-stable formulations of peptides, small molecules, and proteins through various delivery methods, including syringes and auto-injectors. Xeris Biopharma's lead product is Gvoke, a ready-to-use glucagon for treating severe hypoglycemia, while its other products include Keveyis, the first FDA-approved treatment for primary periodic paralysis, and Recorlev, approved for endogenous hypercortisolemia in Cushing's Syndrome. The company is also advancing several product candidates in clinical trials, targeting conditions in endocrinology, neurology, and gastroenterology. Founded in 2005 and headquartered in Chicago, Illinois, Xeris Biopharma aims to improve patient care by providing easier-to-use therapies that enhance treatment outcomes.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is an oral therapy currently in Phase I/IIa clinical trials for the treatment of phenylketonuria. Additionally, Synlogic is developing SYNB1891, an intratumoral synthetic biotic medicine that is undergoing Phase I clinical trials for the treatment of solid tumors and lymphoma. The company is also exploring synthetic biotics for more common conditions, including inflammatory bowel disease and secondary hyperoxaluria. Synlogic has established a collaboration with Ginkgo Bioworks to advance its development of these innovative therapies.

Endologix, Inc. is a medical device company that specializes in the development and manufacturing of minimally invasive treatments for abdominal aortic aneurysms (AAA). The company's product portfolio includes several endovascular aneurysm repair (EVAR) systems, such as the AFX endovascular AAA system, which features a minimally invasive delivery mechanism, and the VELA Proximal Endograft, designed for specific aortic neck anatomies. Additionally, Endologix offers the Ovation abdominal stent graft system and the Nellix endovascular aneurysm sealing (EVAS) system, which effectively seals aneurysms while ensuring adequate blood flow to the legs. The company also provides extensions and accessories to customize and facilitate the delivery of its devices. Endologix markets its products through a direct sales force and a network of third-party distributors and agents. Established in 1992 and based in Irvine, California, Endologix has evolved from its original name, Radiance Medical Systems, Inc., to focus solely on addressing critical aortic-related health issues.

Chondrial Therapeutics LLC is a clinical-stage biotechnology company based in Indianapolis, Indiana, founded in 2013. The company specializes in discovering and developing orphan drugs aimed at treating rare mitochondrial diseases, with a particular focus on Friedreich’s Ataxia. Through its commitment to scientific research, Chondrial Therapeutics seeks to advance innovative therapies for patients affected by these challenging conditions.

Shockwave Medical, Inc. is a medical device company that specializes in intravascular lithotripsy technology aimed at treating calcified plaque in patients with various cardiovascular diseases. The company has developed the Lithoplasty™ family of balloon dilatation catheters, which incorporate lithotripsy electrodes to enhance the compliance of rigid vascular and valvular lesions before low-pressure dilation. This approach minimizes injury to healthy tissue and addresses limitations associated with traditional revascularization technologies. Shockwave offers specific catheters for different applications, including M5 catheters for above-the-knee peripheral artery disease, C2 catheters for coronary artery disease, and S4 catheters for below-the-knee peripheral artery disease. The technology is designed to facilitate more effective angioplasty and improve stent delivery, as well as enhance native tissue preparation for trans-catheter aortic valve replacement. Founded in 2009 and headquartered in Santa Clara, California, Shockwave Medical serves interventional cardiologists, vascular surgeons, and interventional radiologists across the United States and internationally.

Based in King of Prussia, PA, Recovery Centers of America is committed to advocating for some 22.7 million Americans suffering from behavioral health and substance use disorders. The company, which is opening treatment centers throughout the Northeast, is transforming the way treatment is delivered in an industry in desperate need of change. Recovery Centers of America's neighborhood-based Centers for Addiction Medicine are designed based on the latest scientific research that indicates sustained recovery is more likely when patients stay connected to and supported by family and friends, while building other, ongoing support networks. By allowing patients to receive treatment in an atmosphere more akin to a college campus with Starbucks-like appeal, Recovery Centers of America helps overcome the stigma of addiction and its treatment, which is essential to meaningful recovery.

Bridge Medicines LLC offers drug discovery services. It focuses on developing technologies in academic institutions from human proof-of-concept to clinical development. The company develops inhibitors of ENL-YEATS for the treatment of acute leukemias, such as acute myelogenous leukemia and a series of orally active small molecule inhibitors of activated factor XII for the treatment of hereditary angioedema and other inflammatory disorders. Bridge Medicines LLC was founded in 2016 and is based in New York, New York.

SentreHEART, Inc., based in Redwood City, California, is a privately held medical device company that manufacturers the LARIAT Suture Delivery Device for remote delivery of a pre-tied suture loop. Innovation in catheter and suture delivery technology enables physicians to remotely deliver a 40mm pre-tied suture loop for immediate and complete soft tissue closure through access as small as 4.3mm and with no metal, clips or fabrics left behind. Regulatory clearance for soft tissue ligation and approximation has been received in the US, Europe, and Canada.

Oncorus, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative viral immunotherapies for cancer treatment. The company's lead candidate, ONCR-177, utilizes an oncolytic herpes simplex virus type 1 platform and is currently in Phase I clinical trials aimed at treating various cancers. In addition to ONCR-177, Oncorus is advancing the ONCR-GBM program for brain cancer and exploring synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has entered a collaboration with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 in combination with Merck’s immunotherapy. Founded in 2015 and headquartered in Cambridge, Massachusetts, Oncorus is committed to advancing cancer care and has pledged to support cancer research and healthcare initiatives in developing regions through corporate philanthropy.

Ardelyx, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for cardiorenal diseases. Headquartered in Fremont, California, Ardelyx's lead product candidate, tenapanor, has successfully completed Phase 3 clinical trials for treating irritable bowel syndrome with constipation and is also in Phase 3 trials for managing hyperphosphatemia in end-stage renal disease patients undergoing dialysis. The company is advancing RDX013, a small molecule potassium secretagogue, aimed at treating hyperkalemia. Ardelyx is also developing RDX5791, an oral NHE3 sodium transport inhibitor targeting constipation-predominant irritable bowel syndrome and excess dietary sodium absorption, currently in Phase 2 trials. Additionally, RDX002 and RDX009, which inhibit phosphate absorption and target type 2 diabetes, respectively, are in preclinical development. Ardelyx emphasizes non-systemic oral therapeutics that minimize side effects while effectively addressing metabolic disorders. Since its founding in 2007, the company has secured significant funding to support its research and development efforts.

Blade Therapeutics is a discovery stage drug development company. Their mission is to create antifibrotic treatment strategies that address a wide variety of congenital and acquired diseases of fibrosis. Their leadership team has extensive experience at developing drugs that treat fibrotic disorders. They are also partnering with international experts in order to identify and in-license cutting-edge technologies to build a robust pipeline of antifibrotic compounds.